Bone marrow transplantation for chronic myelogenous leukemia

Current Opinion in Oncology

Volumn 10, Issue 2, 1998, Pages 100-107

  Enright, Helen ^a   McGlave, Philip ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BUSULFAN; HYDROXYUREA; INTERFERON; MAFOSFAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; RIBOZYME;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; GENE THERAPY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; MINIMAL RESIDUAL DISEASE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW;

EID: 0031931210     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199803000-00003     Document Type: Review

References (75)

1. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB: Bone marrow transplantation for chronic myeloid leukemia in chronic phase. Ann Intern Med 1988, 108:806-814.
2. Clift RA, Buckner CD, Thomas ED, Appelbaum FR, Bryant E, Bearman SI, Petersen PB, Fisher LD, Anasetti C, Beatty P, Bensmger WI: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991, 77:1660-1665.
3. Enright H, Daniels K, Arthur DC, Dusenbery KE, Kersey JH, Kim J, Miller WJ, Ramsay NKC, Vercellotti GM, Weisdorf DJ, McGlave PB: Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant 1996, 17:537-542.
4. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Vernant JP, Bosi A, et al., for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Bone marrow transplantation for chronic myeloid leukemia: long term results. Bone Marrow Transplant 1993, 12:509-516.
5. Clift RA, Buckner CD, Thomas ED, Bryant T, Anasetti C, Bensinger WI, Bowden R, Deeg HJ, Doney KS, Fisher LD, et al.: Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994, 84:4368-4373.
6. Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, Concannon AJ, Avalos B, Tutschka P, Kapoor N: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992, 80:1353-1357.
7. Silberman G, Crosse MG, Peterson EA, Weston RC, Horowitz MM, Appelbaum FR, Cheson BD: Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med 1994, 331:1063-1067.
8. Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NKC, Arthur D, Verfaillie C, Miller J, et al.: Relapse following non-T-cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplant, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood 1996, 88:714-720.
9. Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringden O, Stone JA, Bortin MM: Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994, 120:646-652.
10. Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, di Bartolomeo P, Boogaerts M, Bosi A, Carreras E, et al., for the Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation: Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 1995, 86:813-818.
11. Mackinnon S, Barnett L, Heller G, O'Reilly RJ: Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994, 83:3409-3416.
12. Huss R, Deeg HJ, Gooley T, Bryant E, Leisenring W, Clift R, Buckner CD, Martin P, Storb R, Appelbaum FR: Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996, 18:767-776. One hundred and ninety-seven patients with CML were investigated following transplant for donor/host chimerism. Fifty-one percent of CML patients were mixed chimeras following transplant. In patients with mixed chimerism beyond 100 days following transplant, the incidence of subsequent relapse was significantly increased. Overall survival and relapse-free survival were improved in mixed compared with complete chimeras, however, partly owing to a decreased incidence of GVHD.
13. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, et al.: Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060. Forty-five patients with CML (39 patients in chronic phase and 6 with accelerated-phase disease) were studied to determine the influence of plasma steady-state levels of busulfan achieved during conditioning on risk of relapse following transplantation. All patients received the same conditioning regimen of busulfan, 16 mg/kg orally, with cyclophosphamide, 120 mg/kg intravenously. Plasma busulfan concentrations at steady state that were below the median were associated with a significantly greater risk of posttransplant cytogenetic relapse (5 of 18 chronic phase and 2 of 4 accelerated phase patients) than in patients with steady-state concentrations above the median, in whom no relapses were observed. The estimated 3-year survival rates for the groups were 82% and 64%, respectively. This study further emphasizes that leukemic cells with proliferative potential clearly often persist following transplant and the importance of the conditioning regimen in eradicating disease.
14. Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM, Reed EC, Gross TG, Kollath J, Nasrati K, et al.: Hematopoietic recovery after allogeneic blood stem cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997, 15:1608-1616. Outcome following transplant is described for 21 patients (including 5 patients with CML) who received allogeneic blood stem cell transplantation and is compared with a historical group of patients receiving marrow transplant. A significantly shorter time to neutrophil recovery and a trend toward earlier platelet and erythrocyte recovery were seen among patients receiving peripheral blood stem cell transplantation. In addition, allogeneic blood stem cell transplantation was associated with fewer platelet transfusions and a shorter hospital stay than m the control group. Although the control group was historical, this study describes a comparable outcome for patients receiving cryopreserved peripheral blood stem cell transplantation and marrow transplantation, with similar rates of acute GVHD and survival to day 100. Future studies, including randomized studies to compare these modes of transplant, are required to determine the long-term survival, incidence of chronic GVHD, and rate of relapse for patients treated using allogeneic peripheral blood stem cells.
15. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, Hunter A, Russell NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995, 85:1666-1672.
16. Davies SM, Shu XO, Blazar BR, Filipovich AH, Kersey JH, Krivit W, McCullough J, Miller WJ, Ramsay NKC, Segall M, et al.: Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 1995, 86:1636-1642.
17. Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F, Ward KN, Hale G, Waldmann H, Hows JM, et al.: Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995, 86:3590-3597.
18. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993, 81:543-550.
19. Devergie A, Apperley JF, Labopin M: European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Bone Marrow Transplant 1997, 20:11-20.
20. Dim G, Rondelli R, Miano M, Vossen J, Gluckman E, Peters C, Bordigoni P, Locatelli F, Miniero R, Ljungman P, et al.: Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: experience of eight European countries. The EBMT Paediatric Diseases Working Party. Bone Marrow Transplant 1996, 18(Suppl 2):80-85. This report describes the European experience of marrow transplant for CML in children. Of 33 evaluable children, engraftment was successful in 96%, with 2 children undergoing subsequent late graft failure. The incidences of acute and chronic GVHD were 63% and 20%, respectively. Transplant-related mortality was high (38%), however, with a relapse rate at 2 years of 14%. The overall 2-year event-free survival was 50%.
21. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR: Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995, 86:3987-3996.
22. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, et al.: Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994, 83:1980-1987.
23. Laporte JP, Gorin NC, Rubenstein P, Lesage S, Portnoi MF, Barbu V, Lopez M, Douay L, Najman A: Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med 1996, 335:167-170.
24. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
25. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, et al.: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638
26. Pichert G, Alyea EP, Soiffer RJ, Roy D-C, Ritz J: Persistence of myeloid progenitor cells expressing BCR/ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood 1994, 84:2109-2114.
27. Lin F, van Rhee F, Goldman JM, Cross NC: Kinetics of increasing bcr-abl transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87:4473-4478.
28. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444. This is a comprehensive report of the results of therapy of posttransplant relapse of CML using donor leukocyte infusions. Twenty-five transplant centers in the United States were surveyed. Complete remission was achieved in 60% of patients with CML. A higher remission rate was seen in patients with chronic phase or cytogenetic relapse (75.7%) than in those in accelerated phase relapse (33.3%) or blast crisis (16.7%) at the time of therapy. For patients achieving complete remission, the actuarial probability of remaining in complete remission at 2 years was 89.6%. Sixty percent of patients developed GVHD, and 18.6% of infusions were complicated by pancytopenia. The development of acute or chronic GVHD was strongly correlated with response.
29. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994, 330:100-106.
30. Kolb H-J, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al., for the European Group for Blood and Marrow Transplantation Working Party on Chronic Leukemia: Graft-versus-leukemia effect of donor lympho-cyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
31. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994, 83:3377-3383.
32. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Niederwieser D, Hoecker P, Greinix HT: Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997, 89:3113-3117.
33. Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P, Dohner H: Detection of chimeric BCR/ABL genes in bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 1994, 83:1922-1928.
34. Frenoy N, Chabli A, Sol O, Goldschmit E, Lemonnier MP, Misset JL, Debuire B: Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts. Leukemia 1994, 8:1411-1414.
35. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ: Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995, 86:2343-2349.
36. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM: Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 1995, 85:2705-2710.
37. Biernaux C, Sels A, Huez G, Stryckmans P: Very low levels of major bcr-abl expression in blood of some healthy individuals, Bone Marrow Transplant 1996, 17(Suppl 3):S45-47.
38. Bhatia R, Verfaillie CM, Miller JS, McGlave PB: Autologous transplantation therapy for chronic myelogenous leukemia. Blood 1997, 89:2623-2634. This comprehensive review of the clinical experience using autologous marrow transplant for CML describes the results of autografts with or without ex vivo purging and the use of in vivo methods to select for predominantly Philadelphia chromosome-negative stem cells for reinfusion by priming and mobilization with chemotherapy and growth factors. The relationship between phase of disease at the time of transplant and outcome following transplant is emphasized, and new strategies to improve outcome, including improved methods of stem cell separation and selection and experimental approaches using antisense oligonucleotides, ribozymes, tyrosine kinase inhibitors, and immunomodulation, are discussed.
39. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A: Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994, 14:407-410.
40. McGlave PB, DeFabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D: Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1991, 343:1486-1488.
41. + cells present in autologous transplants of chronic myelogeous leukemia (CML) contribute to relapse after autologous bone marrow transplantation. Blood 1994, 83:3068-3076.
42. Khouri IF, Kantarjian HM, Talpaz M, Giralt S, Rios MO, Hester JP, Champlin RE, Deisseroth AB: Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myeloid leukemia: the MD Anderson experience. Bone Marrow Transplant 1996, 17:775-779.
43. Carella AM, Cunningham I, Benvenuto F: Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia. J CIm Oncol 1997, 15:1575-1582.
44. Kantarjian HM, Talpaz M, Hester J, Feldman E, Korbling M, Liang J, Rios MB, Smith TL, Calvert L, Deisseroth AB: Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol 1995, 13:553-559.
45. Chalmers EA, Franklin IM, Kelsey SM, Newland AC, Clarke RE, Sproul AM, Crotty G, McCann SR, Fielding A, Goldstone AH, et al.: Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol 1997, 96:627-634. This study reports results of peripheral blood stem cell mobilization in 40 patients using idarubicin and cytarabine. No harvests were reverse transcriptase-PCR negative, but major responses as assessed by cytogenetic and southern blot analysis were seen in 59% and 53% of patients, respectively. Improved responses were seen early in the course of disease. Mortality was 5% during the mobilization phase, and further mortality during the subsequent transplant phase was 15%.
46. Hughes TP, Grigg A, Szer J, Ho J, Ma D, Dale BM, Green RM, Norman JE, Sage RE, Herrmann R, et al.: Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHuG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. Br J Haematol 1997, 96:635-640. Twenty-three patients with newly diagnosed CML were treated with cyclophosphamide and G-CSF to mobilize peripheral blood progenitors. Predominantly Philadelphia chromosome-negative mobilization (0%-25% Philadelphia chromosome-positive cells) was achieved in 30% of patients. This was achieved only in patients with a low Sokal index, however. A low leukocyte count prior to mobilization and a low leukocyte nadir correlated with predominantly Philadelphia chromosome-negative mobilization.
47. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC: Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly-diagnosed as well as established chronic myeloid leukemia. Stood 1996, 88:2162-2171.
48. Podesta M, Piaggio G, Sessarego M, Pitto A, Benvenuto F, Vassallo F, Fugazza G, Carella AM, Frassoni F: Spontaneous exodus of high numbers of normal early progenitor cells (Ph-negative LTC-IC) in the peripheral blood of patients with chronic myeloid leukaemia at the beginning of the disease. Br J Haematol 1997, 97:94-98.
49. Reiffers J, Taylor K, Gluckman E, Gorin N, Carella A, Destree D: Philadelphia negative blood progenitors can be successfully collected with lenogastrim in patients with chronic myeloid leukemia good responders to alfa-interferon. Bone Marrow Transplant 1996, 17(Suppl 1):S4.
50. Carreras E, Sierra J, Rovira M, Urbano-Ispizua A, Martinez C, Nomdedeu B, Cervantes F, Marin P, Rozman C, Monserrat E: Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. Br J Haematol 1997, 96:421-423.
51. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Steiglbauer K, Dewald G, Heimfeld S, et al.: BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early chronic-phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996, 87:4770-4779.
52. - cells reselected from macrophage inflammatory protein 1α + interleukin-3-supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells. Blood 1994, 84:1442-1449.
53. Verfaillie CM, Miller WJ, Boylan K, McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992, 79:1003-1010.
54. Eaves CJ, Cashman JD, Wolpe SD, Eaves AC. Unresponsiveness of primitive chronic myelogenous leukemia cells to macrophage inflammatory protein 1α, an inhibitor of primitive normal cells. Proc Natl Acad Sci USA 1993, 90:12015-12019.
55. Agarwal R, Doren S, Hicks B, Dunbar CE. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood 1995, 85:1306-1312.
56. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B: Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 1997, 89:124-133. This study describes the use of mafosphamide in combination with phosphorothioate antisense oligonucleotides in a murine model of CML. The combination of agents retarded the development of leukemia more effectively than either agent alone; 50% of animals were cured of leukemia. This effect was at least partly medi-ated by increased apoptosis. In addition, pretreatment with mafosphamide was shown to cause increased uptake of oligodeoxynucleotides in vitro.
57. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB: Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Natl Med 1996, 2:561-566. The tyrosine kinase inhibitor CGP 57148 was investigated for its ability to specifically inhibit proliferation and tumor formation by bcr-abl-expressing cells. The agent inhibited growth of more than 90% of CML colony-forming cells (granulocyte-macrophage colony-forming unit and burst-forming-unit-erythroid) but not the growth of normal cells. Further preclinical testing is needed before the potential of this and other tyrosine kinase inhibitors for the treatment of CML is defined.
58. Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V: Selection of myeloid progenitors lacking in bcr-abl mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 1996, 88:3091-3100. This study investigated the effects of the tyrosine kinase inhibitor genistein on proliferation and colony formation of CML and normal cells in bone marrow culture. Genistein suppressed both normal and CML cell proliferation and colony formation, with relative sparing of primitive long-term culture-initiating cells. Although both normal and CML precursors were suppressed, continuous exposure to or pre-incubation with genistein resulted in a decrease in the percentage of bcr-abl-positive progenitors. The suggested mechanism (since genistein does not appear to directly suppress bcr-abl expression) is through induction of apoptosis.
59. Traycoff CM, Srour EF, Dutt P, Fan Y, Cornelia K: The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors. Leukemia 1997, 11:159-167.
60. Zhao R, McIvor S, Verfaillie CM: Development of a retroviral gene transfer strategy that may improve disease-free survival after autografting in CML Blood 1996, 86(Suppl 1):245a. A novel strategy is suggested whereby normal progenitors from the bone marrow of patients with CML woud be retrovirally transduced with a drug resistance gene to allow specific therapy and elimination of nontransduced residual leukemic cells following autografting. The vector would contain the drug-resistance gene linked to a bcr-abl antisense gene to avoid transduction of malignant progenitors. Clinical studies using this approach to autografting are now planned.
61. Lim SH, Coleman S: Chronic myeloid leukemia as an immunological target. Am J Hematol 1997, 54:61-67. This useful review outlines the theoretical basis for considering possible immunologie approaches to the therapy of CML and speculates on future approaches for immunotherapy, including the generation of leukemia-specific T-cell lines, targeting bcr-abl junctional peptides. and adoptive immunotherapy using leukemia-reactive T-cell lines expanded ex vivo.
62. Bosch GJ, Joosten AM, Kessler JH, Melief CJM, Leeksma OC: Recognition of BCR-ABL positive leukemic blasts by human CD34+ T-cells elicited by primary in vitro immunization with a bcr-abl breakpoint peptide. Blood 1996, 88:3522-3527. In vitro immunization of human T cells with a 17-amino-acid peptide representing the p210 bcr-abl fusion region resulted in the generation of peptide-specific CD4+ T-cell lines. DR expression-dependent recognition of allogeneic CML blasts expressing p210 bcr-abl RNA was demonstrated. This and other similar studies suggest that the p210b3a2 gene product can be degraded and expressed for presentation by major histocompatibility complex Class II molecules at the surface of leukemic cells, thus acting as a tumor-specific antigen. It is hoped that these observations lead to new immunotherapeutic strategies for the treatment of CML.
63. Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, Kalbacher H: Bcr-abl leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T-cells found at low frequency in the repertoire of normal donors. Blood 1996, 88:2118-2124.
64. Pierson BA, Miller JS: CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1997, 88:2279-2287.
65. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS: Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996, 87:2476-2485.
66. Miller JS, Verfaillie C, McGlave PB: Expansion and activation of human natural killer cells as therapy for autologous transplantation. Prog Clin Biol Res 1994, 389:39-45.
67. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton D, Kliche K-O, Andreeff M, Champlin RE: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997, 89:1133-1142. This study describes the generation of dendritic cells in culture from patients with CML by incubation of CML marrow with GM-CSF, interleukin-4, and tumor necrosis factor-α. These dendritic cells (derived from the malignant clone) can stimulate autologous T cells with cytotoxic activity against CML cells but low activity against major histocompatibility complex-matched normal bone marrow cells. Cytotoxic activity of dendritic cell-stimulated T cells was four-to sixfold higher than that observed using T cells stimulated with interleukin-2 alone. In addition to direct cytotoxic activity, dendritic cell-stimulated T cells also inhibited proliferation of CML clonogenic precursors in colony forming assays. This approach may lead to the development of adoptive immunotherapy of CML using expanded autologous antileukemic cytotoxic T cells wih enhanced activity against CML cells.
68. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M: Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996, 87:3069-3081.
69. Allen NC, Richards SM, Shepherd PC: UK Medical Research Council randomised, multicentre trial of interferon-alpha for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995, 345:1392-1397.
70. Italian Co-operative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994, 330:820-825.
71. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Quiber W, Löffler H, Hochhaus A, Heinze B, et al., and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994, 84:4064-4077.
72. 2/d subcutaneously for 10 days each month). At randomization, patients were in chronic phase, previously treated only with hydroxyurea, and within 6 months of diagnosis. The rate of hematologic response was greater in the interferon-cytarabine group (66% versus 55%). Major cytogenetic responses (less than 35% Philadelphia chromosome-positive cells in bone marrow) were observed 12 months after randomization in 41% of patients in the interferon-cytarabine group, compared with 24% of the interferon-alone group. In patients receiving interferon with cytarabine, cytogenetic response was complete in 15%, compared with 9% for those receiving interferon alone, and partial in 26% compared with 19%. In both groups, landmark analysis showed a significant survival advantage for patients with a cytogenetic response (complete or partial) compared with those with no response or a minor response. Overall survival after 3 years was significantly greater (85.7%) lor patients treated with interferon with cytarabine than for those treated with interferon alone (79.1%).
73. Horowitz MM, Giralt S, Szydlo RM, Goldman JM, Veum-Stone J: Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia in first chronic phase [abstract]. Blood 1996, 88:682a. This report from the International Bone Marrow Transplant Registry examined the effect of prior interferon therapy on posttransplant outcome for 882 patients undergoing HLA-identical sibling donor marrow transplant in first chronic phase. Prior interferon therapy had no adverse influence on overall survival, leukemia-free survival, or relapse risk following transplant either for patients transplanted within 1 year of diagnosis or for those undergoing transplant later m chronic phase.
74. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, Schaefer UW: Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995, 85:2981-2990.
75. Wandl UB, Butzler R, Niederle N, Kloke O, Mengelkoch B, Becher R, Seeber S, Opalka B: BCR/ABL-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment. Leukemia 1994, 8:776-779.